Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, weight loss injections can make you feel sick, particularly in the first few weeks. Nausea is the most commonly reported side effect of GLP-1 medicines like semaglutide (Wegovy) and tirzepatide (Mounjaro), affecting a significant proportion of people who start treatment. It tends to be mild to moderate, settles as your body adjusts, and is far less likely to be a problem if you know what to expect. These are prescription-only medicines — a prescriber assesses whether they are right for you before anything is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture the moment your DPD delivery turns up, plain box, no branding, a discreet pen inside. You've done your research, you start your first dose, and within a day or two your appetite has dropped noticeably. That part feels like it's working. Then comes the nausea, sometimes a low background queasiness, sometimes something sharper after a meal.
Both semaglutide and tirzepatide slow gastric emptying, food moves out of your stomach more gradually than it normally would. That's part of how they reduce hunger. The trade-off is that if you eat a normal-sized meal, your stomach is already fuller than it realises, and nausea follows. The way these medicines work at a gut-hormone level is also new to your body, which adds to the unsettled feeling in those early weeks.
The good news is that the pattern is well documented. In the clinical trials for both Wegovy and Mounjaro, nausea was highest around the time of the first dose or a dose increase, then fell substantially as weeks passed. Most people do not feel as sick at week eight as they did at week two. The NHS medicines information for tirzepatide lists nausea as common but notes it generally improves over time, that framing is accurate to what people actually experience.
There are real, evidence-consistent steps that reduce how sick you feel. None of them require medication; most require only small changes to when and how you eat.
Eat less at each sitting. The reduced gastric emptying means a portion that felt normal before treatment now feels like too much, so take less than you think you need and stop before you feel full. Slow down. High-fat meals and very spicy food tend to worsen nausea, so keep meals plain during the adjustment period. Staying well hydrated matters, too; sipping water steadily through the day is better than drinking large amounts at once.
Timing can help. Some people find nausea is worse in the morning; others find the hour or two after injection is the worst window. Injecting in the evening before sleep is a common approach, you sleep through the peak. There is no single right answer; it takes a few weeks to learn your own pattern. The questions our prescribers hear most often about early side effects usually have a practical answer like one of these.
If nausea is making it difficult to keep fluids down, your prescriber needs to know. Persistent vomiting can lead to dehydration, which is its own problem. The right response is always to contact your clinical team rather than push through.
Distinguishing normal adjustment from something more serious matters. Mild nausea, loose stools or constipation, belching and a general feeling of fullness are common and expected, especially early on or after a dose increase. Fatigue and headaches in the first week or two are also frequently reported.
Severe, persistent stomach pain (especially pain that reaches through to your back, with or without vomiting) is different. The MHRA issued a Drug Safety Update in January 2026 specifically highlighting acute pancreatitis as a known, though infrequent, serious side effect of GLP-1 medicines: anyone experiencing this pattern of pain should seek urgent medical help and not wait to see if it settles. You can also report suspected side effects via the MHRA's Yellow Card scheme, patient reports genuinely inform ongoing safety monitoring.
Other symptoms worth escalating promptly include signs of a significant allergic reaction, severe or unusual fatigue, or any symptoms that feel disproportionate to what the early-weeks profile suggests. Your prescriber is the right person to judge. Some people also ask whether the medicines affect energy levels more broadly, the evidence on that is covered in detail on our page on tiredness and weight loss injections.
Not everyone feels sick. Some people start treatment and barely notice GI symptoms at all. Others have a rough first fortnight and then feel fine. A smaller group finds nausea persistent enough to affect quality of life, in those cases, a prescriber may recommend staying at the current dose for longer before increasing, or may review whether treatment is right to continue. If you want a fuller picture of what to expect in those early weeks, our page on whether weight loss injections make you feel sick goes through the evidence in more detail.
The titration schedule exists precisely for this reason. Tirzepatide starts at 2.5mg, a dose whose main job is to let your system adapt before the therapeutic doses begin. Semaglutide follows a similar graduated path. Rushing up the dose ladder is associated with worse side effects; the schedule is set by the prescriber, not by the patient. If you are weighing up which medicine might suit you better from a tolerability standpoint, our overview of the leading weight loss injections compares the two profiles without oversimplifying.
If you are considering treatment and want to understand how a prescriber would assess your situation (including your GI history and any other medicines you take) a free consultation with our clinical team is the place to start. Everything is reviewed by a GPhC-registered prescriber before anything is prescribed, and if questions about longer-term physical changes are on your mind, our page on whether weight loss injections affect how you look is worth reading before you begin. Straightforward.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.